Plain-English translation of NCT04552509 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing TrueBeam stereotactic body radiotherapy, a new type of radiation treatment for early-stage prostate cancer. Unlike older radiation methods or surgery, this treatment uses a robotic system to deliver highly precise radiation doses to the prostate from multiple angles. The goal is to see if this approach works as well as or better than traditional treatments, with fewer side effects.
Prostate cancer affects hundreds of thousands of men each year, but current treatment options like surgery, traditional radiation, or seed implants can cause significant side effects and require invasive procedures. This new treatment offers a non-invasive option that could deliver the same powerful radiation doses without catheters, anesthesia, or hospital stays.
As a participant, you would receive radiation treatment using the TrueBeam system over multiple sessions (the exact schedule depends on your cancer risk level). The treatment is non-invasive—no surgery or implants needed. You would have planning scans to map your prostate precisely, and then receive focused radiation beams guided by real-time imaging. The trial will track how well the treatment works and monitor you for any side effects over time.
AI-generated summary from trial data · Aug 30, 2026 · Not medical advice
United States